Immunotherapy for Cervical Cancer

Safa Can EFİLa , Muhammed Bülent AKINCIa
aAnkara Bilkent City Hospital, Clinic of Medical Oncology, Ankara, Türkiye

Efil SC, Akıncı MB. Immunotherapy for cervical cancer. In: Şendur MAN, ed. Current Immunotherapy Landscape for Solid Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.113-8.

ABSTRACT
Globally, cervical cancer ranks as the fourth primary cause of cancer-related deaths among women. Today, surgery, chemotherapy, radiotherapy, and chemoradiation therapy are commonly employed in the standard treatment of cervical cancer. But, patients with locally advanced, recurring, or metastatic cervical cancer have an unmet need for new therapeutics. Human papillomavirus (HPV) infection is the primary cause of cervical cancer. HPV employs a variety of strategies to evade immune surveillance. In recent years, just like in various other cancer types, immunotherapies have been applied in the management of cervical cancer. These encompass immune checkpoint inhibitors, therapeutic vaccines, and adoptive T-cell therapies. For this HPV-driven malignancy that frequently expresses programmed cell death ligand-1 (PD-L-1), immunotherapies are usefull therapy strategies. In this chapter we will give a general summary of the immunological mechanisms driving cervical cancer, as well as the expanding body of clinical data supporting the use of immunotherapy.

Keywords: Cervical cancer; immunotherapy; immune check point inhibitors

Referanslar

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [Crossref]  [PubMed]
  2. Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013;87(1):111-9. [Crossref]  [PubMed]
  3. Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, et al. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol. 2019;134(1):49-57. [Crossref]  [PubMed]  [PMC]
  4. Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998;42(5):1015-23. [Crossref]  [PubMed]
  5. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654-63. [Crossref]  [PubMed]
  6. Shamseddine AA, Burman B, Lee NY, Zamarin D, Riaz N. Tumor Immunity and Immunotherapy for HPV-Related Cancers. Cancer Discov. 2021;11(8):1896-912. [Crossref]  [PubMed]  [PMC]
  7. Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005;37(6):319-24. [Crossref]  [PubMed]  [PMC]
  8. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007;7(1):79-89. [Crossref]  [PubMed]
  9. Prata TT, Bonin CM, Ferreira AM, Padovani CT, Fernandes CE, Machado AP, et al. Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. Immunology. 2015;146(1):113-21. [Crossref]  [PubMed]  [PMC]
  10. Howitt BE, Sun HH, Roemer MG, Kelley A, Chapuy B, Aviki E, et al. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncol. 2016;2(4):518-22. [Crossref]  [PubMed]
  11. Mayadev JS, Enserro D, Lin YG, Da Silva DM, Lankes HA, Aghajanian C, et al. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2020;6(1):92-9. [Crossref]  [PubMed]  [PMC]
  12. Duska LR, Scalici JM, Temkin SM, Schwarz JK, Crane EK, Moxley KM, et al. Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2020;126(22):4948-56. [Crossref]  [PubMed]
  13. Mayadev J, Nunes AT, Li M, Marcovitz M, Lanasa MC, Monk BJ. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. Int J Gynecol Cancer. 2020;30(7):1065-70. [Crossref]  [PubMed]  [PMC]
  14. Lorusso D, Xiang Y, Colombo N, Coleman R, Randall L, Duska L, et al. 261 ENGOT-cx11/GOG 3047/KEYNOTE-A18: phase 3 randomized study of pembrolizumab + chemoradiotherapy for high-risk locally advanced cervical cancer. Int J Gynecol Cancer. 2021;31(Suppl 3):A19-A20. [Crossref]
  15. Monk B, Toita T, Wu X, Limón JC, Zhou Q, Tarnawski R, et al. O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial. Int J Gynecol Cancer. 2022;32(Suppl 3):A2-A3. [Crossref]
  16. Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, et al. Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. JAMA Oncol. 2018 Jul 12;4(7):e173776. [Crossref]  [PubMed]  [PMC]
  17. Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019;37(17):1470-8. [Crossref]  [PubMed]
  18. Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol. 2019;37(31):2825-34. [Crossref]  [PubMed]  [PMC]
  19. Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020;157(1):161-6. [Crossref]  [PubMed]  [PMC]
  20. Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al.; KEYNOTE-826 Investigators. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856-67. [Crossref]  [PubMed]
  21. Kahraman S, Erbas UE, Yalcin B. Who should be treated with pembrolizumab in addition to standard of care in advanced cervical cancer? Med Oncol. 2022;39(3):33. [Crossref]  [PubMed]
  22. Friedman CF, Snyder Charen A, Zhou Q, Carducci MA, Buckley De Meritens A, Corr BR, et al. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. J Immunother Cancer. 2020;8(2):e001126. [Crossref]  [PubMed]  [PMC]
  23. Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, et al.; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med. 2022;386(6):544-55. [Crossref]  [PubMed]
  24. Lan C, Shen J, Wang Y, Li J, Liu Z, He M, et al. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial. J Clin Oncol. 2020;38(34):4095-106. [Crossref]  [PubMed]  [PMC]
  25. O'Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, et al. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecol Oncol. 2021;163(2):274-80. [Crossref]  [PubMed]
  26. Xing Y, Yasinjan F, Du Y, Geng H, Zhang Y, He M, et al. Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials. Front Immunol. 2023;14:1094437. [Crossref]  [PubMed]  [PMC]
  27. Miles B, Safran HP, Monk BJ. Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001. Gynecol Oncol Res Pract. 2017;4:10. [Crossref]  [PubMed]  [PMC]
  28. Huh WK, Brady WE, Fracasso PM, Dizon DS, Powell MA, Monk BJ, et al. Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020;158(3):562-9. [Crossref]  [PubMed]  [PMC]
  29. Petit RG, Mehta A, Jain M, Gupta S, Nagarkar R, Kumar V, et al. ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer. J Immunother Cancer. 2014;2(Suppl 3):P92. [Crossref]
  30. Stevanović S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, et al. A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers. Clin Cancer Res. 2019;25(5):1486-93. [Crossref]  [PubMed]  [PMC]
  31. Doran SL, Stevanović S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, et al. T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. J Clin Oncol. 2019;37(30):2759-68. [Crossref]  [PubMed]  [PMC]